{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-000046","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2023-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.498042+00:00","generated_at":"2026-06-20T21:14:22.417703+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Oncotelic details 2023 pipeline: 10+ OT-101 trials, pancreatic & glioma FPI, BARDA award","bullets":["At least 10 investigator-initiated OT-101 trials planned in 2023 for NSCLC, pancreatic, melanoma, gliomas.","Phase 2/3 pancreatic cancer trial expected FPI 2023; 55% long-term disease control in prior P001 study.","BARDA awarded maximum EZ-BAA funding for OT-101 long COVID; observational trial starts 2023.","Subsidiary Pet2DAO to launch PDAO token and distribute to shareholders/stakeholders in 2023.","R&D costs reduced >95%, G&A >50% per latest 10Q; new CMO and CRO added."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-000046","json":"https://secwatch.observer/filing/0001493152-23-000046.json","markdown":"https://secwatch.observer/filing/0001493152-23-000046.md","text":"https://secwatch.observer/filing/0001493152-23-000046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315223000046/0001493152-23-000046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315223000046/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T21:14:22.417703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}